

INTERNATIONAL CONFERENCE ON PROGRESSION OF ATHEROSCLEROSIS IN ANGINAL SYNDROMES AND HEART TRANSPLANTATION

June 23–24, 1994, Palazzo dei
Congressi, Lugano, Switzerland

Worldwide authorities will discuss the cause, mechanisms, and therapy of disease progression in patients with coronary artery disease and patients who have undergone heart transplantation. The aim of the conference is to give an overview of pathological, biomolecular, and pathophysiological mechanisms responsible for disease progression in ordinary angina syndromes and transplanted hearts.

For information:

PD Dr med A Gallino, MD, Head, Division of Cardiology, Ospedale San Giovanni, 6500 Bellinzona, Switzerland.

University of Glasgow

CLINICAL RESEARCH INITIATIVE IN HEART FAILURE

CARDIOVASCULAR EPIDEMIOLOGIST

This major new Initiative, which has been funded by the Medical Research Council, is seeking to appoint a clinical epidemiologist. The person appointed will be responsible for providing the overall management of the epidemiological aspects of this five year study. The post, which will be on the Clinical Lecturer scale, is a joint appointment between the Departments of Public Health and Cardiology. Applicants should have appropriate clinical and research experience. A postgraduate qualification and experience in epidemiology would be an advantage.

*Informal enquiries to Professor J. McEwan,
Department of Public Health (telephone 041-339
8855 ext 4039).*

Applications, cv together with the names and addresses of three referees, should be submitted to Dr. Henry J. Dargie, Consultant Cardiologist, Western Infirmary, Glasgow, G11 6NT, not later than 14th January, 1994.

PLACES
LIMITED

THE INTERNATIONAL CONGRESS ON SMOKING CESSATION

S.E.C.C.
GLASGOW
5–8 MARCH 1994

The Programme for the International Congress on Smoking Cessation will be of specific interest to practising cardiologists who are involved in all aspects of smoking cessation and smoking-related diseases and has the following aims:

- ◆ To focus on the concept of smoking as a preventable disease by bringing together experts on the pharmacology of nicotine, nicotine dependence and the pathophysiological processes resulting directly from smoking.
- ◆ To consider the changing epidemiology of smoking-related diseases and to debate the interpretation of the statistical basis for establishing an association between both primary and secondary (passive) smoking and specific diseases.
- ◆ To provide a forum for concerned scientists to discuss the current research into methods of stopping patients smoking and to examine currently available and future therapeutic interventions to assist in smoking cessation programmes.

Topics for inclusion

These themes will be covered under the following sections:

- Smoking as a Disease*
- ◆
- Established Risks of Continuing Smoking*
- ◆
- Environmental Tobacco Smoke (ETS)*
- ◆
- Benefits and Problems of Smoking Cessation*
- ◆
- Aids to Cessation*
- ◆
- The Total Approach to Smoking Cessation*

FOR FURTHER INFORMATION PLEASE CONTACT:

Congress Secretariat: Gardiner-Caldwell Communications Ltd, The Old Ribbon Mill, Pitt Street Macclesfield, Cheshire SK11 7PT, UK. Tel. 0625 618507 (16 lines). Fax No. 0625 610260
Co-sponsored by *The Journal of Smoking-Related Disorders*

Congress Chairman

Sir Richard Doll, Oxford, UK

Programme Planning Committee

*Professor J N Diana
Lexington, USA*

*Dr K O Fagerström
Helsingborg, Sweden*

Dr J Y Jeremy, London, UK

Dr D P Mikhailidis, London, UK

*Professor M A H Russell
London, UK*

Scientific Committee (Programme Planning Committee plus)

Professor E Ernst, Exeter, UK

Professor Y Goto, Isehara, Japan

*Professor M Kunze
Vienna, Austria*

Dr D Hoffmann, New York, USA

Professor D Julian, London, UK

*Professor R M Pittilo
Kingston-upon-Thames, UK*

Dr D P L Sachs, Palo Alto, USA

Professor A G Shaper, London, UK


*Dr P Tønnesen, Copenhagen,
Denmark*

Scientific Secretary

A D S Caldwell, Oxford, UK

A beautiful record of cardiological discovery

In the development of modern cardiological drugs chance observation, intense prolonged chemical investigation, studies of disease in animals, and patients' own findings have all played a part, and Arthur Hollman's account of these discoveries makes fascinating reading. A keen amateur botanist who is also a member of the Committee of Management of the Chelsea Physic Garden, and a Fellow of the Linnean Society, Dr Hollman has woven medical and botanical information into succinct and elegantly written articles. His book will be of great value to everyone who is interested in nature's contribution to medicine, including cardiologists, doctors, pharmacists, botanists, herbalists and medical historians.



UK £5.95; Abroad £7.50 (BMA members £5.45 or £7.00)
including postage, by air abroad

Available from BRITISH MEDICAL JOURNAL, PO Box 295,
London WC1H 9TE, major booksellers or the BMJ bookshop in
BMA House. Book tokens accepted (UK only)

Please send me _____ copy/ies of **Plants in Cardiology**

NAME _____

ADDRESS _____

_____ POST CODE _____

I enclose _____ BMA Membership No _____

Please make cheques payable to **British Medical Journal**.
Debit my credit card (please tick box)

Visa American Express Mastercard

Card No. _____

Card expiry date _____

Signature _____

Please send me a book catalogue

[POM] Reviewed August 1993

ABRIDGED PRODUCT INFORMATION

Refer to Data Sheet before prescribing.

INDICATIONS

All grades of essential hypertension and renovascular hypertension. Heart failure (as adjunctive therapy); improves symptoms, and reduces mortality and hospitalisation.

DOSAGE AND ADMINISTRATION

Hypertension: Initially, 5 mg once daily, reduce starting dose to 2.5 mg if over 65 years, on diuretics or renally impaired. Adjust dose according to response; maintenance usually 10-20 mg once daily. Maximum dose 40 mg daily. Diuretic-treated patients – if possible stop diuretic two to three days before starting 'Innovace'. Resume diuretic later if required.

Heart failure (adjunctive therapy): Initially, 2.5 mg daily under medical supervision (hospital initiation for severe heart failure; hospital initiation for high-risk patients is recommended), increasing to the usual maintenance dose of 10-20 mg daily according to tolerability. This dosage schedule has been shown to improve survival.

Impaired renal function: May require a lower maintenance dose. 'Innovace' is dialysable.

CONTRA-INDICATIONS Pregnancy – stop therapy if suspected. Hypersensitivity to 'Innovace'. Patients reacting with angioneurotic oedema to previous ACE-inhibitor treatment.

PRECAUTIONS

Assess renal function prior to therapy with 'Innovace' and during therapy where appropriate.

Renal insufficiency; possibility of hypotension especially in ischaemic heart disease or cerebrovascular disease or in volume-depleted patients; surgery/anaesthesia.

Combination with antihypertensives may increase hypotensive effect. In some patients with bilateral renal artery stenosis increased blood urea and creatinine has been seen, especially in patients treated with diuretics and/or those with renal insufficiency. Minimises thiazide-induced hypokalaemia and hyperuricaemia. Potassium supplements, potassium-sparing diuretics, and potassium-containing salt substitutes are not recommended.

Possible reduced response in Afro-Caribbean patients. Use with caution in breast-feeding mothers. Do not use in aortic stenosis, or outflow tract obstruction. Monitor serum levels of lithium, if lithium salts are given.

ACE inhibitors should be avoided in patients dialysed with high-flux membranes.

SIDE EFFECTS

Side effects include: dizziness, headache. Others include fatigue, asthenia, hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash, cough.

Less commonly, angioneurotic oedema; other hypersensitivity reactions; renal failure; symptomatic hypotension (especially if volume-depleted); severe hypotension (more likely if severe heart failure); hyperkalaemia, hyponatraemia; increases in liver enzymes and serum bilirubin (usually reversible on discontinuation of 'Innovace'); paraesthesiae; impotence.

A complex of symptoms has been reported which may include fever, serositis, vasculitis, myalgia, arthralgia/arthritis, a positive ANA, elevated ESR, eosinophilia and leucocytosis. Rash, photosensitivity or other dermatological manifestations may occur.

BASIC NHS COST

Titration Pack (2.5 mg tablets x 11, 5 mg tablets x 14), £6.12 for 14-day calendar pack. 2.5 mg tablets, £10.00 for bottles of 50. 5 mg tablets, £7.86 for 28-day calendar pack; £14.03 for bottles of 50. 10 mg tablets, £11.03 for 28-day calendar pack; £19.69 for bottles of 50. 20 mg tablets, £13.10 for 28-day calendar pack; £23.40 for bottles of 50.

Product licence numbers:

2.5 mg tablets, 0025/0220; 5 mg tablets, 0025/0194; 10 mg tablets, 0025/0195; 20 mg tablets, 0025/0196.

Issued August 1993.

© denotes registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.

References:

1. Kjekshus, J., and Swedberg, K., *Amer. J. Cardiol.*, 1989, **63**, 26D.
2. The SOLVD Investigators, *New Engl. J. Med.*, 1991, **325**, 293.
3. Cohn, J. N., et al., *New Engl. J. Med.*, 1991, **325**, 303.



Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU

**Two major studies
further reinforce the benefits
of 'Innovace' in
heart-failure treatment**

Live longer...

... than patients treated with conventional therapy or a vasodilator combination. Three major survival studies involving over 3,600 heart-failure patients confirm that the addition of 'Innovace' to optimal diuretic/digoxin treatment can significantly improve survival in mild, moderate and severe heart failure when compared with placebo^{1,2} or a vasodilator combination³

Live better...

... than patients receiving optimal diuretic/digoxin therapy. In the CONSENSUS and SOLVD studies, patients with heart failure who received 'Innovace' in addition to concomitant heart-failure treatment showed further improvements as reflected in the reduced frequency of hospitalisations^{1,2}

Only

INNOVACE[®]

(enalapril maleate, MSD)

CONSENSUS • SOLVD • V-HeFT II
Proving to be essential in mild, moderate and severe heart failure

REFLECTING QUALITY WORLDWIDE



R0039/SP



BS 5750 (Part 2)/
ISO 9002/EN 29002

Certificate Number: FM 14713

Relied upon by leading surgeons, Swann-Morton blades are as worldwide as their reputation for quality.

Alongside their classic surgical range, there are the "Major" orthopaedic blades, "Minor" disposables, and special blades for cervical biopsy and myringotomy. Most recent is the completely new "Fine" range.

Extensively researched, all blades are produced under strict quality control by precise automation, and inspected at every stage.

Swann-Morton always have the blade for the task, uniformly correct in shape, size and weight, and durably sharp - that's why they are famous worldwide!

All products sterilised by
Swann-Morton (Services) Ltd.


Swann-Morton

Swann-Morton Limited,
Owlerton Green, Sheffield S6 2BJ

England

Tel: (0742) 344231 *

Fax: (0742) 314966



MAIL ORDER SERVICE

Located in London, the BMJ Bookshop stocks a comprehensive range of medical titles, including a wide selection of student text books.

We offer a fast and efficient mail order service and books are despatched post free within the UK (overseas customers should add 15% for postage and packing).

Any books in stock will be despatched within 24 hours of receiving your order with payment.

BMJ BOOKSHOP

Any practice, library, institution, hospital or company that would be interested in opening an account with us should contact David Clifton or Peter Elliot for further details.



*1st Class Books-
1st Class Service*

When using your credit card to pay for an order, by telephone, fax or letter please quote your card number and expiry date.

BMJ Bookshop, Burton Street, London WC1H 9JR

☎ 071 383 6244 / 6638

Fax 071 383 6662